J. Palacios

发表

Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer.

J. Fridlyand, D. Pinkel, D. Albertson, 2007, Cancer research.

Deletion of Chromosome 11 q Predicts Response to Anthracycline-Based Chemotherapy in Early Breast Cancer

J. Fridlyand, D. Pinkel, D. Albertson, 2007 .

Loss of heterozygosity in BRCA1 and BRCA2 markers and high‐grade malignancy in breast cancer

Jose M. Silva, J. Palacios, M. Provencio, 2004, Breast Cancer Research and Treatment.

The uniform approach to breast fine-needle aspiration biopsy. National Cancer Institute Fine-Needle Aspiration of Breast Workshop Subcommittees.

M. Bibbo, Kyung-Ja Cho, S. Nasim, 1997, Diagnostic cytopathology.

Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma

F. López-Ríos, F. Rojo, J. Palacios, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer

F. Rojo, J. Albanell, A. Ruíz, 2016, The oncologist.

Characterisation of tumoral markers correlated with ErbB2 (HER2/Neu) overexpression and metastasis in breast cancer

J. Palacios, A. Ridley, J. Timms, 2008, Proteomics. Clinical applications.

A new multidisciplinary Spanish Working Group on Cancer Biomarkers: presentation and aims

E. Álava, A. Ariza, J. Palacios, 2012, Clinical and Translational Oncology.

Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.

Arrate Plazaola, Emilio Alba, Carmen Crespo, 2008, Journal of the National Cancer Institute.

Molecular staging of prostatic cancer with RT-PCR assay for prostate-specific antigen in peripheral blood and lymph nodes: comparison with standard histological staging and immunohistochemical assessment of occult regional lymph node metastases.

J. Palacios, R. Perona, L. Martínez-Piñeiro, 2003, European urology.

Data Set for the Reporting of Endometrial Cancer: Recommendations From the International Collaboration on Cancer Reporting (ICCR)

P. Ip, J. Palacios, X. Matías-Guiu, 2022, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Mutational Screening of BRCA1/2 Genes as a Predictive Factor for Therapeutic Response in Epithelial Ovarian Cancer: A Consensus Guide from the Spanish Society of Pathology (SEAP-IAP) and the Spanish Society of Human Genetics (AEGH)

J. Cigudosa, F. Rojo, A. Osorio, 2019, Virchows Archiv.

Treating KRAS-mutant NSCLC: latest evidence and clinical consequences

F. López-Ríos, J. Palacios, P. Garrido, 2017, Therapeutic advances in medical oncology.

Necitumumab in squamous non-small-cell lung cancer: how to move forward?

J. Palacios, P. Garrido, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer.

F. Rojo, J. Albanell, A. Lluch, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Abnormal frequencies of alleles in polymorphic markers of the 17q21 region is associated with breast cancer.

J. Palacios, F. Bonilla, J. Silva, 1999, Cancer letters.

Classical markers like ER and ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: results from the GEICAM/2002-01 phase II study

J. Palacios, J. Ramírez, E. Carrasco, 2012, Clinical and Translational Oncology.

Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology

J. Palacios, X. Matías-Guiu, R. Guarch, 2017, Clinical and Translational Oncology.

Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis.

F. Rojo, E. Espinosa, J. Palacios, 2017, The oncologist.

Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)

F. López-Ríos, J. Albanell, A. Lluch, 2009, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial

A. Carrato, F. Mulero, A. Lluch, 2016, Clinical Cancer Research.

LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

E. Felip, J. Bosch-Barrera, J. Palacios, 2021, Cancer medicine.

Personalized cancer medicine and the future of pathology

M. Dietel, H. Moch, K. Kerr, 2011, Virchows Archiv.

High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer.

F. Rojo, J. Albanell, A. Ruíz, 2016, The oncologist.

Modified SureSelectQXT Target Enrichment Protocol for Illumina Multiplexed Sequencing of FFPE Samples

J. Palacios, P. Garrido, S. Leskelä, 2018, Biological Procedures Online.

Nabrax: Neoadjuvant therapy of breast cancer with weekly single-agent nab-paclitaxel—Final efficacy and biomarkers analysis of GEICAM 2011-02 trial.

A. Arance, E. Espinosa, J. Palacios, 2014 .

Proposal for the creation of a national strategy for precision medicine in cancer: a position statement of SEOM, SEAP, and SEFH

J. Palacios, E. de Álava, X. Matías-Guiu, 2017, Clinical and Translational Oncology.

Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.

J. Mayordomo, A. Ruíz, A. Lluch, 2008, Journal of the National Cancer Institute.

P1-06-04: PAM50 Proliferation Index Predicts Response to Weekly Adjuvant Paclitaxel in Node-Positive Operable Breast Cancer.

C. Perou, I. Stijleman, P. Bernard, 2011 .

[Clinical challenges and implications of intratumor heterogeneity].

J. Palacios, E. de Álava, X. Matías-Guiu, 2019, Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia.